Cargando…
Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies
BACKGROUND: Patients with malignant haematological disease and especially those who require intensive care have an increased risk of bleeding and thrombosis, but none of these data were obtained in ICU patients only. We assessed the incidence of bleeding and thrombotic complications, use of blood pr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725397/ https://www.ncbi.nlm.nih.gov/pubmed/29230562 http://dx.doi.org/10.1186/s13613-017-0341-y |
_version_ | 1783285512870559744 |
---|---|
author | Russell, Lene Holst, Lars Broksø Kjeldsen, Lars Stensballe, Jakob Perner, Anders |
author_facet | Russell, Lene Holst, Lars Broksø Kjeldsen, Lars Stensballe, Jakob Perner, Anders |
author_sort | Russell, Lene |
collection | PubMed |
description | BACKGROUND: Patients with malignant haematological disease and especially those who require intensive care have an increased risk of bleeding and thrombosis, but none of these data were obtained in ICU patients only. We assessed the incidence of bleeding and thrombotic complications, use of blood products and risk factors for bleeding in an adult population of ICU patients with haematological malignancies. METHODS: We screened all patients with acute leukaemia and myelodysplastic syndrome admitted to a university hospital ICU during 2008–2012. Bleeding in ICU was scored according to the WHO grading system, and risk factors were evaluated using unadjusted and adjusted analyses. RESULTS: In total, 116 of 129 ICU patients were included; their median length of stay was 7 (IQR 2–16) days. Of these, 66 patients (57%) had at least one bleeding episode in ICU; they bled for 3 (2–6) days and most often from lower and upper airways and upper GI tract. Thirty-nine (59%) of the 66 patients had severe or debilitating (WHO grade 3 or 4) bleeding. The median platelet count on the day of grade 3 or 4 bleeding was 23 × 10(9) per litre (IQR 13–39). Nine patients (8%) died in ICU following a bleeding episode; five of these had intra-cerebral haemorrhage. Platelet count on admission was associated with subsequent bleeding (adjusted odds ratio 1.18 (95% CI 1.03–1.35) for every 10 × 10(9) per litre drop in platelet count, p = 0.016). Eleven of the 116 patients (9%) developed a clinically significant thrombosis in ICU, which was the cause of death in four patients. The median platelet count was 20 × 10(9) per litre (15–48) at the time of thrombosis. The patients received a median of 6 units of red blood cells, 1 unit of fresh frozen plasma and 8 units of platelet concentrates in ICU. CONCLUSIONS: Severe and debilitating bleeding complications were frequent in our ICU patients with haematological malignancies, but thrombosis also occurred in spite of low platelet counts. Platelet count on ICU admission was associated with subsequent bleeding. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13613-017-0341-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5725397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-57253972017-12-14 Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies Russell, Lene Holst, Lars Broksø Kjeldsen, Lars Stensballe, Jakob Perner, Anders Ann Intensive Care Research BACKGROUND: Patients with malignant haematological disease and especially those who require intensive care have an increased risk of bleeding and thrombosis, but none of these data were obtained in ICU patients only. We assessed the incidence of bleeding and thrombotic complications, use of blood products and risk factors for bleeding in an adult population of ICU patients with haematological malignancies. METHODS: We screened all patients with acute leukaemia and myelodysplastic syndrome admitted to a university hospital ICU during 2008–2012. Bleeding in ICU was scored according to the WHO grading system, and risk factors were evaluated using unadjusted and adjusted analyses. RESULTS: In total, 116 of 129 ICU patients were included; their median length of stay was 7 (IQR 2–16) days. Of these, 66 patients (57%) had at least one bleeding episode in ICU; they bled for 3 (2–6) days and most often from lower and upper airways and upper GI tract. Thirty-nine (59%) of the 66 patients had severe or debilitating (WHO grade 3 or 4) bleeding. The median platelet count on the day of grade 3 or 4 bleeding was 23 × 10(9) per litre (IQR 13–39). Nine patients (8%) died in ICU following a bleeding episode; five of these had intra-cerebral haemorrhage. Platelet count on admission was associated with subsequent bleeding (adjusted odds ratio 1.18 (95% CI 1.03–1.35) for every 10 × 10(9) per litre drop in platelet count, p = 0.016). Eleven of the 116 patients (9%) developed a clinically significant thrombosis in ICU, which was the cause of death in four patients. The median platelet count was 20 × 10(9) per litre (15–48) at the time of thrombosis. The patients received a median of 6 units of red blood cells, 1 unit of fresh frozen plasma and 8 units of platelet concentrates in ICU. CONCLUSIONS: Severe and debilitating bleeding complications were frequent in our ICU patients with haematological malignancies, but thrombosis also occurred in spite of low platelet counts. Platelet count on ICU admission was associated with subsequent bleeding. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13613-017-0341-y) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-12-11 /pmc/articles/PMC5725397/ /pubmed/29230562 http://dx.doi.org/10.1186/s13613-017-0341-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Russell, Lene Holst, Lars Broksø Kjeldsen, Lars Stensballe, Jakob Perner, Anders Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies |
title | Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies |
title_full | Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies |
title_fullStr | Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies |
title_full_unstemmed | Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies |
title_short | Risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies |
title_sort | risks of bleeding and thrombosis in intensive care unit patients with haematological malignancies |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725397/ https://www.ncbi.nlm.nih.gov/pubmed/29230562 http://dx.doi.org/10.1186/s13613-017-0341-y |
work_keys_str_mv | AT russelllene risksofbleedingandthrombosisinintensivecareunitpatientswithhaematologicalmalignancies AT holstlarsbroksø risksofbleedingandthrombosisinintensivecareunitpatientswithhaematologicalmalignancies AT kjeldsenlars risksofbleedingandthrombosisinintensivecareunitpatientswithhaematologicalmalignancies AT stensballejakob risksofbleedingandthrombosisinintensivecareunitpatientswithhaematologicalmalignancies AT perneranders risksofbleedingandthrombosisinintensivecareunitpatientswithhaematologicalmalignancies |